<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DF79FD97-AFC0-4E12-B081-3BF8E8ABCB2C"><gtr:id>DF79FD97-AFC0-4E12-B081-3BF8E8ABCB2C</gtr:id><gtr:name>Wellcome Trust Case Control Consortium 2 (WTCCC)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Clinical Neurosciences</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DF79FD97-AFC0-4E12-B081-3BF8E8ABCB2C"><gtr:id>DF79FD97-AFC0-4E12-B081-3BF8E8ABCB2C</gtr:id><gtr:name>Wellcome Trust Case Control Consortium 2 (WTCCC)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/7BB1FCBA-BC86-4DE3-9404-E41BB4849178"><gtr:id>7BB1FCBA-BC86-4DE3-9404-E41BB4849178</gtr:id><gtr:firstName>David</gtr:firstName><gtr:surname>Beeson</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FM006824%2F1"><gtr:id>CC70CA42-0345-4C66-80B5-C357734459F5</gtr:id><gtr:title>Disease mechanisms and therapy for inherited disorders of the neuromuscular synapse.</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/M006824/1</gtr:grantReference><gtr:abstractText>This programme of work will study a group of inherited diseases called congenital myasthenic syndromes (CMS) in which the transfer of the signal for muscle contraction from nerve to muscle is disrupted. These are rare disorders, present in around 1 in 100,000 of the UK population, that may be life-threatening and can cause severe disability in children and adults, but we are frequently able to work out what is going wrong and as a result devise appropriate therapy. In the last two years we have found mutations in four new genes that cause CMS and have been at the forefront of showing that treatments usually used for asthma can result in remarkable improvement for our patients. Research success led our laboratory to be the basis for a National Referral Centre for CMS, and through this service our goal is to provide tailored therapy for each of our patients. To move towards this goal this programme of work will address the following questions:

i) Which genes are responsible for additional cases of CMS? We have around 40 cases in which we have not been able to find the genetic cause of the patient's condition. Patients, above all, want a definitive diagnosis. We will use the latest DNA sequencing techniques to search for the genetic defects in these patients, and new patients who are referred to our clinic.

ii) How do the genetic defects in the genes that we recently identified cause disease? If we can work out how the mutations are disrupting the information transfer from nerves to muscle we can often devise appropriate therapy. Therefore if we can find out how the mutations in these four new genes result in disease it should help in their treatment.

iii) Can we find new available treatments? We have found that certain drugs commonly used for asthma can work exceptionally well for some of our patients. We want to find out exactly how these are having their effects and then see if there are other similar but potentially even better drugs available.

iv) Can we experiment to find novel treatments? The site where information is passed from nerve to muscle is called a synapse. We have noted that when one of the proteins we study, DOK7, is produced at high levels in muscles is generates greatly enlarged synapses in their correct location, which we call 'super synapses'. When we generated these 'super synapses' in a disease model for DOK7 CMS is completely cured the disease. We want to perform studies on the super synapses to define exactly why they work so well and also we want to try this novel therapy in other CMS disease models. Moreover, it could potentially be applicable to some other more common diseases that feature defects in the neuromuscular junction synapse such as motor neurone disease or spinal muscular atrophy.</gtr:abstractText><gtr:technicalSummary>Congenital myasthenic syndromes (CMS) stem from genetic defects that affect signal transmission at the neuromuscular synapse. They provide a rare example of genetic muscle disorders that are treatable if the underlying molecular mechanisms are understood. At least 19 causative genes have been uncovered with mutations identified in proteins involved in signal transfer, synaptic stability, or glycosylation. 
There are four objectives to this proposal:
 i) to use next generation sequencing techniques to resolve the genetics behind our residual undefined CMS cases;
 ii) to find out the mechanisms through which glycosylation mutations impair neuromuscular transmission;
 iii) to study molecular mechanism to explain how treatment with beta2-adrenergic receptor (beta2-ADR) agonists results in dramatic clinical improvement;
 iv) when over-expressed in muscle DOK7 generates correctly located but greatly enlarged neuromuscular junctions or 'super synapses'. We will test the potential of these 'super synapses' as a novel gene therapy.
Within the laboratory there is expertise for the analysis of neuromuscular junction proteins. Next generation sequencing techniques will be used to screen for genes with new CMS-causing mutations. Molecular genetic (including CRISPR/Cas9 genome editing), biochemical and fluorescence microscopy techniques will be used to generate and study disease models in fibroblast or muscle cells. Effects of beta2-ADR agonists will be studied in transgenic models, in myotube cultures, and within AChR clusters. Detailed analysis of molecular dynamics within AChR clusters will use super-resolution microscopy in combination with temporal and spatial optogenetic stimulation. Therapy, including adeno-associated virus delivery of DOK7 to generate 'super synapses', will be given to transgenic mouse disease models and analysed in vivo by strength tests and electromyography and ex vivo by electrophysiology, microscopy, and biochemical analysis.</gtr:technicalSummary><gtr:potentialImpactText>Impact statement: 
The research proposed in this application is predicted to have a direct and immediate impact on patients with congenital myasthenic syndrome and their care. It may have longer term but significant implications for patients with autoimmune myasthenia gravis, and patients with some less common neurological disorders such as some forms of limbic encephalitis.
At an immediate level the results of a genetic diagnosis will be fed back to patients through the Oxford-based National Diagnostic and Advisory Service for Congenital Myasthenic Syndromes.
For patients and their families this provides:
i) A definitive diagnosis
ii) A basis for genetic counselling, prenatal diagnosis, and prognostic advice.
iii) Inappropriate diagnosis and treatments will be avoided. For challenging cases, prior to genetic analysis, the patient will often have had immunosuppression and undergone a thymectomy. 
There are at least six different effect drugs that can be used either independently or in combination for the congenital myasthenic syndromes. Knowledge of the disease mechanism for particular mutations provides the basis for appropriate therapy. Correct therapy can have a dramatic beneficial effect both on muscle strength and quality of life. For instance, we first defined DOK7 mutations as a cause of congenital myasthenic syndrome and by treating these patients appropriately we are often able to get patients who were wheel chair-dependent leading near normal lives. A tailored treatment service will continue to provide
iv) Dramatic improvement in quality of life for patients and their families. 
For the broader UK economy appropriate therapy for a disabling and sometimes life-threatening disorder will:
i) Reduced clinical burden of these disorders
ii) Reduce or prevent ITU admissions which are frequent for patients with certain subtypes of congenital myasthenic syndrome, but may occur for all forms.
iii) Improved performance and quality of life in employment.
iv) Reduce burden of caring performed by family members and social services
v) Facilitate employment
vi) Reduce the overall costs in benefits that are required for a disabled person
vii) Reduce the requirement for one-to-one support in school or outside
Other NHS benefits:
i) The NHS will benefit from definitive diagnosis
ii) Improved education of clinicians on managing these disorders
iii) Increased understanding of principle of translating basic research into clinical solutions e.g. 'bench to beside'

These benefits will be rapidly transferred from laboratory to patients through the National Service for Congenital Myasthenic Syndromes, where patients are quickly offered consultations once the genetics and disease mechanism of their condition is defined.

Patients are regularly updated on advances from the laboratory through Patient open days, or through the Myasthenia Gravis Association and Muscular Dystrophy Campaign charities.
Named researchers have been part of this programme for many years and are uniquely qualified to educate clinical fellows and research students on these specialised disorders and the techniques used for functional analysis of mutations.

We are exploring novel therapeutic approaches based on the biology of the DOK7 protein. Though at an early research stage, this approach may potentially have applications in a wide variety of neuromuscular disorders that feature defective neuromuscular junction structure during disease progression such as ALS, SMA, or sarcopenia which are intractable and multifactorial diseases.</gtr:potentialImpactText><gtr:fund><gtr:end>2019-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2014-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1501251</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Centre for Neuromuscular Diseases</gtr:department><gtr:description>MRC neuromuscular centre</gtr:description><gtr:id>7642708F-48CA-4C17-8D46-EE9ED8DAC723</gtr:id><gtr:impact>Publications identifying a new gene in which mutations can underlie congenital myasthenic syndromes, and characterisation of the syndrome phenotype</gtr:impact><gtr:outcomeId>XdDbWLLRfNG-1</gtr:outcomeId><gtr:partnerContribution>Provision of patients and scientific data</gtr:partnerContribution><gtr:piContribution>Supplied patient data, mutation data, functional laboratory studies</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Wellcome Trust Case Control Consortium 2 (WTCCC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>WGS500 consortium</gtr:description><gtr:id>52378C99-184A-4114-A2D3-533C10C5EC9D</gtr:id><gtr:impact>Pathogenic mutations in new genes identified

Cossins et al. (submitted)</gtr:impact><gtr:outcomeId>qA3axZbqj3M-1</gtr:outcomeId><gtr:partnerContribution>Identification of appropriate DNA samples

Functional analysis of variants to determine if they are pathogenic</gtr:partnerContribution><gtr:piContribution>Providing patient DNA and analysis of identified variants for identification rare Mendelian disorders</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Wellcome Trust Centre for Human Genetics</gtr:department><gtr:description>WGS500 consortium</gtr:description><gtr:id>4C679179-8A0F-419E-998E-A8B4E5CB94CF</gtr:id><gtr:impact>Pathogenic mutations in new genes identified

Cossins et al. (submitted)</gtr:impact><gtr:outcomeId>qA3axZbqj3M-2</gtr:outcomeId><gtr:partnerContribution>Identification of appropriate DNA samples

Functional analysis of variants to determine if they are pathogenic</gtr:partnerContribution><gtr:piContribution>Providing patient DNA and analysis of identified variants for identification rare Mendelian disorders</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Structural Genomics Consortium (SGC)</gtr:department><gtr:description>Crystal structures</gtr:description><gtr:id>A23EBF85-AFFB-455C-A0D1-0619CC5594DF</gtr:id><gtr:impact>N/A</gtr:impact><gtr:outcomeId>56dd5931295234.38287457-1</gtr:outcomeId><gtr:partnerContribution>We supply information on mutants and constructs for the expression of these proteins, our partners peform crystalisation and structural analysis</gtr:partnerContribution><gtr:piContribution>Collaborating on crystalisation of mutant proteins of mutations found in CMS patients</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Patient information pamphlet</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>ADE77AEC-840A-4A7A-8ED8-8877A00B6BC9</gtr:id><gtr:impact>The pamphlet is used by families to inform them about their disorder and to take to their schools to inform them about the disorder that the children have. This enables the schools to understand the childs condition and to put in place appropriate safeguards and facilities to ensure the patient is safe and to enable adaptations to allow a full potential for learning to be in place.

Should help school, social workers to understand patient disabilities and their special needs when at school.</gtr:impact><gtr:outcomeId>A7rGnj4ns5f</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:url>http://www.ouh.nhs.uk/services/referrals/neurosciences/myasthenia.aspx</gtr:url><gtr:year>2010,2011,2012,2013,2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Congenital myasthenic syndrome open day</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>C04EC131-4FE5-4D19-AB8C-BFE82986E0E5</gtr:id><gtr:impact>Patient day. Patients are given a series of lectures on scientific research updates, and then in the afternoon there are a series of workshops for particular patient groups where needs that have been identified or areas of special interest are addressed. Typically this might involve treatments, exercise, benefits, future therapy updates.

Patients and researchers are both enthused about the research effort</gtr:impact><gtr:outcomeId>885B5E80795</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:url>http://www.ouh.nhs.uk/services/referrals/neurosciences/myasthenia.aspx</gtr:url><gtr:year>2006,2008,2010,2013,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talks to patient group</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>D0B073E7-DEBC-4C70-8AE5-A834C6A79C4A</gtr:id><gtr:impact>Updating patient support groups on the research activities.


Patients are always interested in their disorders and usually ask lots of questions.</gtr:impact><gtr:outcomeId>i8j9FUUHPJB</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>Pre-2006,2006,2007,2008,</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lectures to patient groups</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>7B4DA74D-6E6F-4CED-BF51-6A97EFF8D275</gtr:id><gtr:impact>Regularly give talks to small patient groups and parents who have an obvious interest in inherited myasthenic disorders

Useful patient researcher contact.</gtr:impact><gtr:outcomeId>290D2A0AFEA</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Work experience</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>FC3B10DD-5634-4381-A6BE-E68D6713599D</gtr:id><gtr:impact>Individual students spend a week in the laboratory learning about scientific research.

School comes back each year requesting further pupil experience.</gtr:impact><gtr:outcomeId>FXxCfJfBJfB</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2008,2009,2010,2011,2012</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>85000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Studentship supported by the UK Myasthenia charity</gtr:description><gtr:end>2019-09-02</gtr:end><gtr:fundingOrg>Myaware</gtr:fundingOrg><gtr:id>0733B885-0203-4F76-87BA-0D980850155A</gtr:id><gtr:outcomeId>58beca6a9b1ff7.58933309</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>256000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Wellcome Trust Bloomsbury Centre</gtr:department><gtr:description>Wellcome Trust Clinical Training fellowship</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:fundingRef> 103406/Z/13/Z</gtr:fundingRef><gtr:id>2C4E6801-5954-4E19-8EB2-CF530391DD82</gtr:id><gtr:outcomeId>58becc13f1fef0.58916497</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Defined treatment for patient subsets</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>E79101D5-6EE6-4712-813D-E6A235BE08C4</gtr:id><gtr:impact>Defined that ephedrine or other b2-adrenergic receptor agonists have a dramatic beeneficial effect for patients with DOK7 CMS. Thus this is now standard treatment for this genetic condition. many patients regain ambulation from previous requirement of a wheel chair. We have now defined other patient subsets for which appropriate treatment combinations leads to life-transforming improvement in quality of life. May patients regain ambulation from previously being wheel chair-bound.</gtr:impact><gtr:outcomeId>VUnFmaDdovE</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>6F90F2AA-74A3-4257-9104-ECFA4A783E8F</gtr:id><gtr:title>Myasthenic syndromes due to defects in COL13A1 and in the N-linked glycosylation pathway.</gtr:title><gtr:parentPublicationTitle>Annals of the New York Academy of Sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9a5861e43624583f637d02658bd01795"><gtr:id>9a5861e43624583f637d02658bd01795</gtr:id><gtr:otherNames>Beeson D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0077-8923</gtr:issn><gtr:outcomeId>5aa1423c23e9f8.86214085</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8D1D4E54-F61C-40E6-8D30-9931E8662706</gtr:id><gtr:title>Tubular Aggregates and Cylindrical Spirals Have Distinct Immunohistochemical Signatures.</gtr:title><gtr:parentPublicationTitle>Journal of neuropathology and experimental neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8655b80f35da06543063892dc80fc48b"><gtr:id>8655b80f35da06543063892dc80fc48b</gtr:id><gtr:otherNames>Brady S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-3069</gtr:issn><gtr:outcomeId>58bec618b3f333.08701082</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8AFE070A-BB23-42F1-9C1C-48E80342C889</gtr:id><gtr:title>Factors influencing success of clinical genome sequencing across a broad spectrum of disorders.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0595a7d8bf7c30b67c83c71fcc8d9e98"><gtr:id>0595a7d8bf7c30b67c83c71fcc8d9e98</gtr:id><gtr:otherNames>Taylor JC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>56dd53c6800a80.64586135</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D5101E30-3415-462A-9AB6-A6A6E87D0AE5</gtr:id><gtr:title>Neuromuscular disease. DOK7 gene therapy benefits mouse models of diseases characterized by defects in the neuromuscular junction.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9b5524adce7053d097dd945a4f2e5e96"><gtr:id>9b5524adce7053d097dd945a4f2e5e96</gtr:id><gtr:otherNames>Arimura S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn><gtr:outcomeId>5464bbb83c8c11.33214651</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7FB7FC06-3373-4610-AE68-AE3355BA54E8</gtr:id><gtr:title>Congenital myasthenic syndromes and the neuromuscular junction.</gtr:title><gtr:parentPublicationTitle>Current opinion in neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aa0b6ef76225dc642b86c7e03e3cfd59"><gtr:id>aa0b6ef76225dc642b86c7e03e3cfd59</gtr:id><gtr:otherNames>Rodr?guez Cruz PM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1350-7540</gtr:issn><gtr:outcomeId>5464bbb813f1c1.96044015</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A27D0E98-E0DD-48EA-880D-00697F317A30</gtr:id><gtr:title>Late presentations of congenital myasthenic syndromes: How many do we miss?</gtr:title><gtr:parentPublicationTitle>Muscle &amp; nerve</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b3b29542b17b67fe02cd9668f7484cd7"><gtr:id>b3b29542b17b67fe02cd9668f7484cd7</gtr:id><gtr:otherNames>Garg N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0148-639X</gtr:issn><gtr:outcomeId>58bec6d096e023.51134470</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7875B578-46C8-4C29-B201-80548BD8A270</gtr:id><gtr:title>Congenital Myasthenic Syndrome Type 19 Is Caused by Mutations in COL13A1, Encoding the Atypical Non-fibrillar Collagen Type XIII a1 Chain.</gtr:title><gtr:parentPublicationTitle>American journal of human genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/69719be8c0d997003b15d9b90bc3e6af"><gtr:id>69719be8c0d997003b15d9b90bc3e6af</gtr:id><gtr:otherNames>Logan CV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0002-9297</gtr:issn><gtr:outcomeId>56dd54796ca986.58258301</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>27B03327-B6BC-4437-AD53-960023CB23A5</gtr:id><gtr:title>Fast-channel congenital myasthenic syndrome with a novel acetylcholine receptor mutation at the a-e subunit interface.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8f022b8687d82dc8df9d836a488d074d"><gtr:id>8f022b8687d82dc8df9d836a488d074d</gtr:id><gtr:otherNames>Webster R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>pm_540e159e159c5bfb6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>15BFAB35-20D9-4083-B137-52BFABBED35C</gtr:id><gtr:title>Molecular characterization of congenital myasthenic syndromes in Spain.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aa72e1487b5c9616d7251983f1a41ed9"><gtr:id>aa72e1487b5c9616d7251983f1a41ed9</gtr:id><gtr:otherNames>Natera-de Benito D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>5aa1423bbe2b04.07482303</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C10899F0-EC3B-4F68-B169-29F013B4559E</gtr:id><gtr:title>Salbutamol and ephedrine in the treatment of severe AChR deficiency syndromes.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aa0b6ef76225dc642b86c7e03e3cfd59"><gtr:id>aa0b6ef76225dc642b86c7e03e3cfd59</gtr:id><gtr:otherNames>Rodr?guez Cruz PM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>56dd541d1e7aa1.04274308</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D40C1DA9-7516-4677-9E3A-2F4EE213BEFE</gtr:id><gtr:title>A rare c.183_187dupCTCAC mutation of the acetylcholine receptor CHRNE gene in a South Asian female with congenital myasthenic syndrome: a case report.</gtr:title><gtr:parentPublicationTitle>BMC neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/209f39b43a0a141b3a9fcc985f600ddd"><gtr:id>209f39b43a0a141b3a9fcc985f600ddd</gtr:id><gtr:otherNames>Chang T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1471-2377</gtr:issn><gtr:outcomeId>58bec61900e2d6.32821000</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4BEDA54D-5871-418F-9EA1-5DD12CEDC67A</gtr:id><gtr:title>Congenital myopathies with secondary neuromuscular transmission defects; a case report and review of the literature.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aa0b6ef76225dc642b86c7e03e3cfd59"><gtr:id>aa0b6ef76225dc642b86c7e03e3cfd59</gtr:id><gtr:otherNames>Rodr?guez Cruz PM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>5464bbb7e24362.17217598</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FE9CA147-2A1C-4289-AB28-A7E6B83C1AC8</gtr:id><gtr:title>Next generation sequencing in a large cohort of patients presenting with neuromuscular disease before or at birth.</gtr:title><gtr:parentPublicationTitle>Orphanet journal of rare diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/66f8e40e8307fafbef0963f9b378e1c3"><gtr:id>66f8e40e8307fafbef0963f9b378e1c3</gtr:id><gtr:otherNames>Todd EJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1750-1172</gtr:issn><gtr:outcomeId>56dd544fc40931.57375509</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8D1AC2D6-B10E-4E88-9097-4D0B3FB4FF65</gtr:id><gtr:title>Collagen Q--a potential target for autoantibodies in myasthenia gravis.</gtr:title><gtr:parentPublicationTitle>Journal of the neurological sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f4b4b7c8a3715a48e7d2d3a0eb278716"><gtr:id>f4b4b7c8a3715a48e7d2d3a0eb278716</gtr:id><gtr:otherNames>Zoltowska Katarzyna M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-510X</gtr:issn><gtr:outcomeId>56dd526d183166.07537426</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7ADE1BF4-7BD7-4FED-ACC9-A7A53888078B</gtr:id><gtr:title>Mobility shift of beta-dystroglycan as a marker ofgene-related muscular dystrophy.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3594f340e4a1627490ba4eeba3e02389"><gtr:id>3594f340e4a1627490ba4eeba3e02389</gtr:id><gtr:otherNames>Sarkozy A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>5aa1423ca27375.64375748</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>110AB47D-E27D-425F-9AE9-85F35120CC24</gtr:id><gtr:title>Muscle magnetic resonance imaging in congenital myasthenic syndromes.</gtr:title><gtr:parentPublicationTitle>Muscle &amp; nerve</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cb4a622948ab7690627e2ef7352ddf2e"><gtr:id>cb4a622948ab7690627e2ef7352ddf2e</gtr:id><gtr:otherNames>Finlayson S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0148-639X</gtr:issn><gtr:outcomeId>585d738ba6f213.87738443</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3DB1D58E-CC29-4DE1-AB5D-E40CD0C105C4</gtr:id><gtr:title>Mutations in GMPPB cause congenital myasthenic syndrome and bridge myasthenic disorders with dystroglycanopathies.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ef1daab582c85c7641d8fd3dea00cc9e"><gtr:id>ef1daab582c85c7641d8fd3dea00cc9e</gtr:id><gtr:otherNames>Belaya K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>56dd53f4ea02c0.55281023</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A05E40B4-9816-4FBD-90CB-6B2703354D70</gtr:id><gtr:title>Clinical features of the myasthenic syndrome arising from mutations in GMPPB.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aa0b6ef76225dc642b86c7e03e3cfd59"><gtr:id>aa0b6ef76225dc642b86c7e03e3cfd59</gtr:id><gtr:otherNames>Rodr?guez Cruz PM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>585d3b627f7cb8.62013462</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>19FBACB4-2055-44CC-BC0D-5932835895AA</gtr:id><gtr:title>Congenital myasthenic syndrome caused by mutations in DPAGT.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d7d7dab9bcd362c812ec7147699561da"><gtr:id>d7d7dab9bcd362c812ec7147699561da</gtr:id><gtr:otherNames>Klein A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>56dd51d9a61b84.54107531</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BF2430F7-C122-4007-9F14-372DEC45B0CE</gtr:id><gtr:title>Congenital myasthenic syndromes: recent advances.</gtr:title><gtr:parentPublicationTitle>Current opinion in neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9a5861e43624583f637d02658bd01795"><gtr:id>9a5861e43624583f637d02658bd01795</gtr:id><gtr:otherNames>Beeson D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1350-7540</gtr:issn><gtr:outcomeId>58bec61967f8b7.38521199</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6BAEABE6-AD51-4982-9761-3026B95525C3</gtr:id><gtr:title>Therapeutic strategies for congenital myasthenic syndromes.</gtr:title><gtr:parentPublicationTitle>Annals of the New York Academy of Sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/52329ae785e789fb6117f1ddca3cd12b"><gtr:id>52329ae785e789fb6117f1ddca3cd12b</gtr:id><gtr:otherNames>Lee M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0077-8923</gtr:issn><gtr:outcomeId>5aa1423c7ce8d4.86592414</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B669325B-4A38-47DD-A551-27DF6B54D1E7</gtr:id><gtr:title>Novel SEA and LG2 Agrin mutations causing congenital Myasthenic syndrome.</gtr:title><gtr:parentPublicationTitle>Orphanet journal of rare diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2cf655951c3ee15b532584d9bdc2de65"><gtr:id>2cf655951c3ee15b532584d9bdc2de65</gtr:id><gtr:otherNames>Xi J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1750-1172</gtr:issn><gtr:outcomeId>5aa1423bf0e823.25621599</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>988C0DC8-DDD7-448A-A9A1-7EDE115FE385</gtr:id><gtr:title>Inherited disorders of the neuromuscular junction: an update.</gtr:title><gtr:parentPublicationTitle>Journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aa0b6ef76225dc642b86c7e03e3cfd59"><gtr:id>aa0b6ef76225dc642b86c7e03e3cfd59</gtr:id><gtr:otherNames>Rodr?guez Cruz PM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0340-5354</gtr:issn><gtr:outcomeId>5464bbb863a5a1.51785135</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A80185D7-7478-4B3B-83E9-CF04036F288D</gtr:id><gtr:title>Novel mutations in the C-terminal region of GMPPB causing limb-girdle muscular dystrophy overlapping with congenital myasthenic syndrome.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/84299561b806b1664b65dc87dd000920"><gtr:id>84299561b806b1664b65dc87dd000920</gtr:id><gtr:otherNames>Luo S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>5aa1423b6208b1.97287421</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3CB8B32C-336E-4335-BC74-9C65F0522425</gtr:id><gtr:title>Multiple roles of integrin-a3 at the neuromuscular junction.</gtr:title><gtr:parentPublicationTitle>Journal of cell science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/71f88baf01813d0d79455ffa1fbec2d3"><gtr:id>71f88baf01813d0d79455ffa1fbec2d3</gtr:id><gtr:otherNames>Ross JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0021-9533</gtr:issn><gtr:outcomeId>5aa1423b900242.78515407</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1ABB3192-C9CF-4D13-93D2-F7D558172A46</gtr:id><gtr:title>Serological and experimental studies in different forms of myasthenia gravis.</gtr:title><gtr:parentPublicationTitle>Annals of the New York Academy of Sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/574f973bede4fd9f446edfa9f6f58020"><gtr:id>574f973bede4fd9f446edfa9f6f58020</gtr:id><gtr:otherNames>Vincent A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0077-8923</gtr:issn><gtr:outcomeId>5aa1423c57e716.62137012</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B4682EB3-EB30-4946-94DA-9E2F994609CB</gtr:id><gtr:title>Clinical Features and Diagnostic Usefulness of Antibodies to Clustered Acetylcholine Receptors in the Diagnosis of Seronegative Myasthenia Gravis.</gtr:title><gtr:parentPublicationTitle>JAMA neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aa0b6ef76225dc642b86c7e03e3cfd59"><gtr:id>aa0b6ef76225dc642b86c7e03e3cfd59</gtr:id><gtr:otherNames>Rodr?guez Cruz PM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2168-6149</gtr:issn><gtr:outcomeId>56dd5393195159.25398095</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AD70FD30-2691-410F-B393-D9EA9DE6EACB</gtr:id><gtr:title>Salbutamol-responsive fetal acetylcholine receptor inactivation syndrome.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e80a0eea8ed154e1c5f88abb07aa57e8"><gtr:id>e80a0eea8ed154e1c5f88abb07aa57e8</gtr:id><gtr:otherNames>Allen NM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>58bec6d0c5a021.80126488</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>69300CF0-E27D-4FF4-9126-A70EFD0B14A8</gtr:id><gtr:title>How common is childhood myasthenia? The UK incidence and prevalence of autoimmune and congenital myasthenia.</gtr:title><gtr:parentPublicationTitle>Archives of disease in childhood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/31a74d80cec158af1b676534d75a1d5e"><gtr:id>31a74d80cec158af1b676534d75a1d5e</gtr:id><gtr:otherNames>Parr JR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0003-9888</gtr:issn><gtr:outcomeId>5464bbb78d7283.51443576</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>139A58FF-54C3-43A6-A794-72B8F41ED2B9</gtr:id><gtr:title>Silencing of Dok-7 in Adult Rat Muscle Increases Susceptibility to Passive Transfer Myasthenia Gravis.</gtr:title><gtr:parentPublicationTitle>The American journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/19f7be6c1f8942c43d5378ab1188c063"><gtr:id>19f7be6c1f8942c43d5378ab1188c063</gtr:id><gtr:otherNames>Gomez AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0002-9440</gtr:issn><gtr:outcomeId>58bec61938d942.83434820</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/M006824/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>149FA87E-B8CD-4FFC-B515-EAD312BED03B</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Musculoskeletal</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>DD81206B-5EB4-4BCC-AEF7-808A64606E0E</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>